Israel - Inggris - Ministry of Health

trima israel pharmaceutical products maabarot ltd - methylphenidate hydrochloride - tablets prolonged release - methylphenidate hydrochloride 54 mg - methylphenidate - for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - Inggris - Ministry of Health

trima israel pharmaceutical products maabarot ltd - methylphenidate hydrochloride - tablets prolonged release - methylphenidate hydrochloride 54 mg - methylphenidate - for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - Inggris - Ministry of Health

bioavenir ltd, israel - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - oxycodone hydrochloride 10 mg; naloxone hydrochloride (as dihydrate) 5 mg - oxycodone and naloxone - indicated for the relief of moderate to severe pain. the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

Israel - Inggris - Ministry of Health

bioavenir ltd, israel - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - oxycodone hydrochloride 20 mg; naloxone hydrochloride (as dihydrate) 10 mg - oxycodone and naloxone - indicated for the relief of moderate to severe pain. the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

Israel - Inggris - Ministry of Health

bioavenir ltd, israel - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - oxycodone hydrochloride 30 mg; naloxone hydrochloride (as dihydrate) 15 mg - oxycodone and naloxone - indicated for the relief of moderate to severe pain. the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

Israel - Inggris - Ministry of Health

bioavenir ltd, israel - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - oxycodone hydrochloride 40 mg; naloxone hydrochloride (as dihydrate) 20 mg - oxycodone and naloxone - indicated for the relief of moderate to severe pain. the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

Israel - Inggris - Ministry of Health

bioavenir ltd, israel - naloxone hydrochloride (as dihydrate); oxycodone hydrochloride - tablets prolonged release - oxycodone hydrochloride 5 mg; naloxone hydrochloride (as dihydrate) 2.5 mg - oxycodone and naloxone - indicated for the relief of moderate to severe pain. the oxycodone component is indicated for the relief of moderate to severe pain in adults who require continuous around-the-clock opioid analgesia for several days or more. the opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.